- Home
- PEB vs ARVN Comparison
PEB vs ARVN Comparison
Compare PEB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEB
- ARVN
- Stock Information
- Founded
- PEB 2009
- ARVN 2015
- Country
- PEB United States
- ARVN United States
- Employees
- PEB N/A
- ARVN N/A
- Industry
- PEB Real Estate Investment Trusts
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- PEB Real Estate
- ARVN Health Care
- Exchange
- PEB Nasdaq
- ARVN Nasdaq
- Market Cap
- PEB 1.1B
- ARVN 456.2M
- IPO Year
- PEB 2009
- ARVN 2018
- Fundamental
- Price
- PEB $10.44
- ARVN $7.63
- Analyst Decision
- PEB Hold
- ARVN Buy
- Analyst Count
- PEB 7
- ARVN 21
- Target Price
- PEB $11.71
- ARVN $20.53
- AVG Volume (30 Days)
- PEB 2.6M
- ARVN 2.0M
- Earning Date
- PEB 07-23-2025
- ARVN 07-29-2025
- Dividend Yield
- PEB 0.38%
- ARVN N/A
- EPS Growth
- PEB N/A
- ARVN N/A
- EPS
- PEB N/A
- ARVN N/A
- Revenue
- PEB $1,459,506,000.00
- ARVN $426,900,000.00
- Revenue This Year
- PEB $1.63
- ARVN $4.26
- Revenue Next Year
- PEB $2.98
- ARVN N/A
- P/E Ratio
- PEB N/A
- ARVN N/A
- Revenue Growth
- PEB 2.19
- ARVN 498.74
- 52 Week Low
- PEB $7.42
- ARVN $5.90
- 52 Week High
- PEB $15.12
- ARVN $34.11
- Technical
- Relative Strength Index (RSI)
- PEB 59.74
- ARVN 53.52
- Support Level
- PEB $9.83
- ARVN $7.09
- Resistance Level
- PEB $10.15
- ARVN $7.89
- Average True Range (ATR)
- PEB 0.32
- ARVN 0.37
- MACD
- PEB 0.07
- ARVN 0.01
- Stochastic Oscillator
- PEB 88.19
- ARVN 55.67
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.